#USA #New York #Halper Sadeh #CMRX #GLYC

Overview of Halper Sadeh LLC's Investigation

Halper Sadeh LLC, a prominent law firm focused on investor rights, is currently conducting investigations into two companies: Chimerix, Inc. (NASDAQ: CMRX) and GlycoMimetics, Inc. (NASDAQ: GLYC). This action is prompted by concerns regarding potential violations of federal securities laws as well as breaches of fiduciary duties toward shareholders.

Chimerix, Inc. and its Proposed Sale

Chimerix has proposed selling itself to Jazz Pharmaceuticals plc for $8.55 per share in cash. This transaction has raised red flags for investors, prompting Halper Sadeh to investigate whether the price offered reflects the true value of the company and whether the shareholders are receiving fair treatment. The firm emphasizes that shareholders are entitled to have their rights upheld, and there may be options to seek increased compensation or additional disclosures during this transaction.

Rights of Chimerix Shareholders

If you own shares in Chimerix, it’s imperative to understand your rights regarding this sales transaction. The firm is available for free consultations to discuss potential actions you can take to protect your investments. Those interested can reach out to Halper Sadeh for detailed insights into how they can navigate this situation effectively.

GlycoMimetics, Inc. and its Merger

Simultaneously, GlycoMimetics is undergoing a merger with Crescent Biopharma, which is expected to leave its current shareholders with only about 3.1% ownership in the newly merged entity. This significant dilution of shares raises questions about the fairness and transparency of the transaction, leading to Halper Sadeh's scrutiny.

Rights of GlycoMimetics Shareholders

Just like with Chimerix, GlycoMimetics shareholders have options. Halper Sadeh encourages them to seek legal counsel to explore possibilities of increasing their stakes or demanding transparency in the merger process. The firm’s commitment to ensuring that shareholder rights are respected is evident in their proactive approach to this merger.

Halper Sadeh LLC's Commitment

Halper Sadeh LLC has made a name for itself by representing investors globally who have fallen prey to corporate misconduct and securities fraud. Their team of attorneys has a history of achieving significant corporate reforms and recovering financial losses for defrauded investors.

Legal Fees

A notable aspect of Halper Sadeh's representation is their contingency fee arrangement, meaning clients won’t incur out-of-pocket expenses for legal fees unless the case is won. This approach is designed to make legal representation accessible for all shareholders seeking justice.

Conclusion

In summary, both Chimerix and GlycoMimetics are currently in pivotal situations that could affect their shareholders significantly. Investors are encouraged to act swiftly to safeguard their interests. For comprehensive information regarding their rights and potential next steps, shareholders should contact Halper Sadeh LLC.

For further assistance, Daniel Sadeh and Zachary Halper can be reached at (212) 763-0060, or by email at [email protected] or [email protected].

While the investigations are ongoing, the outcomes could have far-reaching implications in ensuring that shareholder rights are adequately honored during these significant corporate transitions.